An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder

Trial Profile

An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine
  • Indications Opioid abuse
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Indivior
  • Most Recent Events

    • 13 Apr 2018 Results presented in an Indivior media release.
    • 13 Apr 2018 According to an Indivior media release, data will be presented as a late-breaking poster at the American Society of Addiction Medicine (ASAM) 49th Annual Conference.
    • 30 Nov 2017 According to an FDA media release, the US FDA has approved buprenorphine (Sublocade) for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top